FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:155-160 January 18, 1996 Number 3 Next

	Full Text PDF Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Hemoccult II, a widely used guaiac test for fecal occult blood, has a low sensitivity for detecting colorectal neoplasms in asymptomatic patients at average risk. In such patients, the performance characteristics of screening tests developed to improve on Hemoccult II are not known.

Methods A set of three fecal occult-blood tests — Hemoccult II; Hemoccult II Sensa, a more sensitive guaiac test; and HemeSelect, an immunochemical test for human hemoglobin — was mailed to all patients 50 years of age or older who were scheduled for personal health appraisals at the Kaiser Permanente Medical Center in Oakland, California. The performance of each test and of a combination test (HemeSelect to confirm positive Hemoccult II Sensa results) was evaluated by identifying screened patients who had colorectal neoplasms (carcinoma or a polyp >1 cm in diameter) in the two years after screening.

Results Of the 10,702 eligible patients, 8104 (75.7 percent) had at least one interpretable sample and were screened on the basis of at least one test; 96 percent of these patients had complete two-year follow-up. The sensitivity of the tests for detecting carcinoma was lowest with Hemoccult II (37.1 percent; 95 percent confidence interval, 19.7 to 54.6 percent), intermediate with the combination test (65.6 percent; 95 percent confidence interval, 47.6 to 83.6 percent) and with HemeSelect (68.8 percent; 95 percent confidence interval, 51.1 to 86.4 percent), and highest with Hemoccult II Sensa (79.4 percent; 95 percent confidence interval, 64.3 to 94.5 percent). The specificity for detecting carcinoma was 86.7 percent with Hemoccult II Sensa, 94.4 percent with HemeSelect, 97.3 percent with the combination test, and 97.7 percent with Hemoccult II. HemeSelect and the combination test detected more colorectal carcinomas and polyps than Hemoccult II, with only slight increases in the number of colonoscopies needed.

Conclusions HemeSelect and a combination test in which HemeSelect is used to confirm positive Hemoccult II Sensa results improve on Hemoccult II in screening patients for colorectal carcinoma.

Source Information

From the Department of Medicine, Kaiser Permanente Medical Center (J.E.A., A.L.A.); and the Division of Research, Kaiser Permanente Medical Care Program (I.S.T., L.J.R.) — both in Oakland, Calif. Presented in part at the 93rd Annual Meeting of the American Gastroenterological Association, San Francisco, May 9–15, 1992, and at the 94th Annual Meeting, Boston, May 15–21, 1993.

Address reprint requests to Dr. Allison at the Department of Medicine, Kaiser Permanente Medical Center, 280 W. MacArthur Blvd., Oakland, CA 94611-5693.

Full Text of this Article

Related Letters:

Improving the Fecal Occult-Blood Test
Allison J. E., Tekawa I. S., Ransom L. J., Adrain A. L., Ransohoff D. F., Lang C. A.
Extract | Full Text  
N Engl J Med 1996; 334:1607-1608, Jun 13, 1996. Correspondence

Occult Gastrointestinal Bleeding in Celiac Sprue
Duane W. C., Heneghan M. A., McCarthy C. F., Fine K. D.
Extract | Full Text  
N Engl J Med 1996; 335:752-753, Sep 5, 1996. Correspondence

This article has been cited by other articles:

• Subramanian, S., Bobashev, G., Morris, R. J. (2009). Modeling the Cost-Effectiveness of Colorectal Cancer Screening: Policy Guidance Based on Patient Preferences and Compliance. Cancer Epidemiol. Biomarkers Prev. 18: 1971-1978 [Abstract] [Full Text]  
• Takai, T., Kanaoka, S., Yoshida, K.-i., Hamaya, Y., Ikuma, M., Miura, N., Sugimura, H., Kajimura, M., Hishida, A. (2009). Fecal Cyclooxygenase 2 Plus Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal Cancer Screening. Cancer Epidemiol. Biomarkers Prev. 18: 1888-1893 [Abstract] [Full Text]  
• Grazzini, G., Ciatto, S., Cislaghi, C., Castiglione, G., Falcone, M., Mantellini, P., Zappa, M., The Working Group of Regional Reference Centre for, (2008). Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence. J Med Screen 15: 175-181 [Abstract] [Full Text]  
• Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R. C. Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P. (2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin. Chem. 54: e11-e79 [Abstract] [Full Text]  
• Malila, N., Oivanen, T., Malminiemi, O., Hakama, M. (2008). Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ 337: a2261-a2261 [Abstract] [Full Text]  
• Whitlock, E. P., Lin, J. S., Liles, E., Beil, T. L., Fu, R. (2008). Screening for Colorectal Cancer: A Targeted, Updated Systematic Review for the U.S. Preventive Services Task Force. ANN INTERN MED 149: 638-658 [Abstract] [Full Text]  
• Chin-Hong, P. V., Berry, J. M., Cheng, S.-C., Catania, J. A., Costa, M. D., Darragh, T. M., Fishman, F., Jay, N., Pollack, L. M., Palefsky, J. M. (2008). Comparison of Patient- and Clinician-Collected Anal Cytology Samples to Screen for Human Papillomavirus-Associated Anal Intraepithelial Neoplasia in Men Who Have Sex with Men. ANN INTERN MED 149: 300-306 [Abstract] [Full Text]  
• Sung, J J Y, Lau, J Y W, Young, G P, Sano, Y, Chiu, H M, Byeon, J S, Yeoh, K G, Goh, K L, Sollano, J, Rerknimitr, R, Matsuda, T, Wu, K C, Ng, S, Leung, S Y, Makharia, G, Chong, V H, Ho, K Y, Brooks, D, Lieberman, D A, Chan, F K L, for The Asia Pacific Working Group on Colorectal C, (2008). Asia Pacific consensus recommendations for colorectal cancer screening. Gut 57: 1166-1176 [Abstract] [Full Text]  
• Levin, B., Lieberman, D. A., McFarland, B., Smith, R. A., Brooks, D., Andrews, K. S., Dash, C., Giardiello, F. M., Glick, S., Levin, T. R., Pickhardt, P., Rex, D. K., Thorson, A., Winawer, S. J., for the American Cancer Society Colorectal Cancer, (2008). Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58: 130-160 [Abstract] [Full Text]  
• Guittet, L, Launoy, G (2008). Diagnostic accuracy of immunochemical faecal occult blood tests according to number of samples and positivity threshold. J Med Screen 15: 48-49 [Full Text]  
• Boyle, J. T. (2008). Gastrointestinal Bleeding in Infants and Children. Pediatr. Rev. 29: 39-52 [Full Text]  
• Allison, J. E., Sakoda, L. C., Levin, T. R., Tucker, J. P., Tekawa, I. S., Cuff, T., Pauly, M. P., Shlager, L., Palitz, A. M., Zhao, W. K., Schwartz, J. S., Ransohoff, D. F., Selby, J. V. (2007). Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance Characteristics. JNCI J Natl Cancer Inst 99: 1462-1470 [Abstract] [Full Text]  
• Mandel, J. S. (2007). Which Colorectal Cancer Screening Test Is Best?. JNCI J Natl Cancer Inst 99: 1424-1425 [Full Text]  
• Tappenden, P., Chilcott, J., Eggington, S., Sakai, H., Karnon, J., Patnick, J. (2007). Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56: 677-684 [Abstract] [Full Text]  
• Levi, Z., Rozen, P., Hazazi, R., Vilkin, A., Waked, A., Maoz, E., Birkenfeld, S., Leshno, M., Niv, Y. (2007). A Quantitative Immunochemical Fecal Occult Blood Test for Colorectal Neoplasia. ANN INTERN MED 146: 244-255 [Abstract] [Full Text]  
• Guittet, L, Bouvier, V, Mariotte, N, Vallee, J P, Arsene, D, Boutreux, S, Tichet, J, Launoy, G (2007). Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56: 210-214 [Abstract] [Full Text]  
• Roy, H. K., Backman, V., Goldberg, M. J. (2006). Colon cancer screening: the good, the bad, and the ugly.. Arch Intern Med 166: 2177-2179 [Full Text]  
• Kovacs, D. J., Berk, T. (2006). Gastrointestinal Bleeding of Obscure Origin Undetected by Multiple Tests for Fecal Occult Blood and Diagnosed Only by Capsule Endoscopy: A Case Report. J Am Board Fam Med 19: 641-642 [Abstract] [Full Text]  
• Frossard, J.-L., de Peyer, R., Worthley, D. L., Cole, S. R., Young, G. P., Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H. (2005). Fecal DNA for Colorectal-Cancer Screening. NEJM 352: 1384-1385 [Full Text]  
• Segnan, N., Senore, C., Andreoni, B., Arrigoni, A., Bisanti, L., Cardelli, A., Castiglione, G., Crosta, C., DiPlacido, R., Ferrari, A., Ferraris, R., Ferrero, F., Fracchia, M., Gasperoni, S., Malfitana, G., Recchia, S., Risio, M., Rizzetto, M., Saracco, G., Spandre, M., Turco, D., Turco, P., Zappa, M., SCORE2 Working Group-Italy, (2005). Randomized Trial of Different Screening Strategies for Colorectal Cancer: Patient Response and Detection Rates. JNCI J Natl Cancer Inst 97: 347-357 [Abstract] [Full Text]  
• Haug, U., Brenner, H. (2005). A Simulation Model for Colorectal Cancer Screening: Potential of Stool Tests with Various Performance Characteristics Compared with Screening Colonoscopy. Cancer Epidemiol. Biomarkers Prev. 14: 422-428 [Abstract] [Full Text]  
• Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Turnbull, B. A., Ross, M. E., the Colorectal Cancer Study Group, (2004). Fecal DNA versus Fecal Occult Blood for Colorectal-Cancer Screening in an Average-Risk Population. NEJM 351: 2704-2714 [Abstract] [Full Text]  
• Lleonart, M. E., Ramon y Cajal, S., Groopman, J. D., Friesen, M. D. (2004). Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Res 32: e53-e53 [Abstract] [Full Text]  
• Walsh, J. M. E., Terdiman, J. P. (2003). Screening for Colorectal Cancer--Reply. JAMA 290: 192-192 [Full Text]  
• Belch, J. J. F., Topol, E. J., Agnelli, G., Bertrand, M., Califf, R. M., Clement, D. L., Creager, M. A., Easton, J. D., Gavin, J. R. III, Greenland, P., Hankey, G., Hanrath, P., Hirsch, A. T., Meyer, J., Smith, S. C., Sullivan, F., Weber, M. A. (2003). Critical Issues in Peripheral Arterial Disease Detection and Management: A Call to Action. Arch Intern Med 163: 884-892 [Full Text]  
• Walsh, J. M. E., Terdiman, J. P. (2003). Colorectal Cancer Screening: Scientific Review. JAMA 289: 1288-1296 [Abstract] [Full Text]  
• Castiglione, G., Zappa, M. (2003). Debate on colorectal cancer screening by faecal occult blood. Ann Oncol 14: 342-344 [Full Text]  
• Levin, B., Brooks, D., Smith, R. A., Stone, A. (2003). Emerging Technologies in Screening for Colorectal Cancer: CT Colonography, Immunochemical Fecal Occult Blood Tests, and Stool Screening Using Molecular Markers. CA Cancer J Clin 53: 44-55 [Abstract] [Full Text]  
• Crespi, M., Lisi, D. (2002). Is colorectal cancer screening by fecal occult blood feasible?. Ann Oncol 13: 47-50 [Full Text]  
• Strul, H., Arber, N. (2002). Fecal occult blood test for colorectal cancer screening. Ann Oncol 13: 51-56 [Full Text]  
• Harewood, G. C., McConnell, J. P., Harrington, J. J., Mahoney, D. W., Ahlquist, D. A. (2002). Detection of Occult Upper Gastrointestinal Tract Bleeding: Performance Differences in Fecal Occult Blood Tests. Mayo Clin Proc. 77: 23-28 [Abstract]  
• Allison, J. E., Selby, J., Launoy, G., Atlas, S. A., Finkelstein, C., Goss, J. R., Church, C. F., Greenberg, M. J., Wendt, E., Lieberman, D., Detsky, A. S. (2001). Screening for Colorectal Cancer. NEJM 345: 1850-1852 [Full Text]  
• Allison, J. E., Ransohoff, D. F., Pignone, M., Mandel, J. S., Church, T. R., Ederer, F. (2001). The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer. NEJM 344: 1022-1023 [Full Text]  
• Frazier, A. L., Colditz, G. A., Fuchs, C. S., Kuntz, K. M. (2000). Cost-effectiveness of Screening for Colorectal Cancer in the General Population. JAMA 284: 1954-1961 [Abstract] [Full Text]  
• Sonnenberg, A., Delco, F., Inadomi, J. M. (2000). Cost-Effectiveness of Colonoscopy in Screening for Colorectal Cancer. ANN INTERN MED 133: 573-584 [Abstract] [Full Text]  
• Luboldt, W., Bauerfeind, P., Wildermuth, S., Marincek, B., Fried, M., Debatin, J. F. (2000). Colonic Masses: Detection with MR Colonography. Radiology 216: 383-388 [Abstract] [Full Text]  
• Kronborg, O, Ugstad, M, Fuglerud, P, Johne, B, Hardcastle, J, Scholefield, J H, Vellacott, K, Moshakis, V, Reynolds, J R (2000). Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 46: 795-800 [Abstract] [Full Text]  
• Lurie, J. D., Welch, H. G. (1999). Diagnostic Testing Following Fecal Occult Blood Screening in the Elderly. JNCI J Natl Cancer Inst 91: 1641-1646 [Abstract] [Full Text]  
• Rockey, D. C. (1999). Occult Gastrointestinal Bleeding. NEJM 341: 38-46 [Full Text]  
• Towler, B., Irwig, L., Glasziou, P., Kewenter, J., Weller, D., Silagy, C. (1998). A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult. BMJ 317: 559-565 [Abstract] [Full Text]  
• Rockey, D. C., Koch, J., Cello, J. P., Sanders, L. L., McQuaid, K. (1998). Relative Frequency of Upper Gastrointestinal and Colonic Lesions in Patients with Positive Fecal Occult-Blood Tests. NEJM 339: 153-159 [Abstract] [Full Text]  
• Simon, J. B., Fletcher, R. H., Simon, J. B., Fletcher, R. H. (1998). Should All People over the Age of 50 Have Regular Fecal Occult-Blood Tests?. NEJM 338: 1151-1155 [Full Text]  
• Levin, B., Hess, K., Johnson, C. (1997). Screening for Colorectal Cancer: A Comparison of 3 Fecal Occult Blood Tests. Arch Intern Med 157: 970-976 [Abstract]  
• Mulcahy, H. E, Farthing, M. J G, O'Donoghue, D. P (1997). Fortnightly review: screening for asymptomatic colorectal cancer. BMJ 314: 285-285 [Full Text]  
• Duane, W. C., Heneghan, M. A., McCarthy, C. F., Fine, K. D. (1996). Occult Gastrointestinal Bleeding in Celiac Sprue. NEJM 335: 752-753 [Full Text]  
• Urena, P., Petrover, M., Levin, N. W., Gotch, F., Malhotra, D., Tzamaloukas, A. H., Ballinger, A. B., Fairclough, P. D., Clark, M. L., Farthing, M. J.G., Kotanko, P., Ifudu, O., Feldman, J., Friedman, E. A. (1996). Intensity of Hemodialysis and Response to Erythropoietin. NEJM 334: 1669-1671 [Full Text]  
• Allison, J. E., Tekawa, I. S., Ransom, L. J., Adrain, A. L., Ransohoff, D. F., Lang, C. A. (1996). Improving the Fecal Occult-Blood Test. NEJM 334: 1607-1608 [Full Text]  
• (1996). OCCULT BLOOD TESTING FOR COLORECTAL CANCER. JWatch General 1996: 3-3 [Full Text]  
• Ransohoff, D. F., Lang, C. A. (1996). Improving the Fecal Occult-Blood Test. NEJM 334: 189-190 [Full Text]